WE DISCOVER AND DEVELOP NOVEL AND

DIFFERENTIATED THERAPIES IN CANCER AND BEYOND

ADDRESS UNMET MEDICAL NEEDS FOR PATIENTS IN CHINA AND GLOBALLY

Founded in 2016, we have established a robust in-house R&D engine underpinned by an outstanding discovery team and a multi-dimensional discovery platform. We have strategically designed and developed a rich pipeline of 10+ small molecule programs focused on oncology.

01---

Pipeline

Clinical-Stage Pipeline

Program

IND

Phase I/Ia

Phase Ib/II

Pivotal

NDA/Commercial

Rights

Precision / Targeted Oncology

Pimicotinib (ABSK021) CSF-1R

TGCT

China:

Ex-China: Abbisko*

Pimicotinib (ABSK021) CSF-1R

cGvHD

China:

Ex-China: Abbisko*

Pimicotinib (ABSK021) CSF-1R

Solid tumors, mono/combo

China:

Ex-China: Abbisko*

Irpagratinib (ABSK011) FGFR4

FGF19+ HCC

Global

Irpagratinib (ABSK011) FGFR4

FGF19+ HCC, combo with atezolizumab

Global

Fexagratinib (ABSK091) Pan-FGFR

FGFR-alt UC, mono/combo with tislelizumab

Global

(partnered with )

ABSK061F GFR2/3

Solid tumors

Global

ABSK061F GFR2/3

Solid tumors, combo

Global

ABSK061F GFR2/3

ACH

Global

ABSK121F GFR-resistant mutations

Solid tumors

Global

ABSK112 EGFR Exon20

NSCLC

Global

ABSK012 FGFR4 mutations

RMS and Solid tumors

Global

ABK3376 (AST2303) EGFR C797S

EGFR-mut NSCLC

Partner-led development

Greater China:

Ex-China: Abbisko

ABSK131 PRMT5*MTA

Solid tumors

Global

Other / Immuno-Oncology

Mavorixafor (ABSK081) CXCR4

WHIM**

Greater China: Abbisko

Ex-China:

ABSK043 Oral PD-L1

Solid tumors

Global

ABSK043 Oral PD-L1

NSCLC, combo with furmonertinib

Global

ABSK051 CD73

Solid tumors

Global

Annotations:

* Merck has an exclusive option for ex-China rights.

** X4 has obtained the market approval of Xolremdi (mavorixafor) from the US FDA for patients 12 years of age and older with WHIM syndrome.

Preclinical Pipeline

Program

Lead identification

Lead Optimization

IND enabling

IND approval

Rights

P017 Synthetic lethal

Solid tumors

Global

P018 Synthetic lethal

Solid tumors

Global

ABSK141 KRAS G12D

Solid tumors

Global

P021 Pan-KRAS

Solid tumors

Global

P019 Undisclosed

Solid tumors

Global

P020 ADC

Solid tumors

Global

P151 Undisclosed

Non-oncology indication

Global

(co-owned with )

Founders

-------------------------------------------------

Our company was founded by a group of experienced drug hunters with strong passion, proven track records in drug discovery, and rich experience in managing multiple large R&D organizations.

Dr. Yao-Chang Xu

Founder & CEO

Dr. Yao-Chang Xu

Founder & CEO

Dr. Yao-Chang Xu has more than 25 years of drug dis...

Dr. Hongping Yu

Co-founder, CSO

Dr. Hongping Yu

Co-founder, CSO

Dr. Hongping Yu has worked in drug discovery and de...

Our Scientific Focus

small molecule precision oncology & immuno-oncology therapies

Our Pipeline

Consists of a broad range of small-molecule
precision-oncology and immuno-oncology product candidates

Partnership

We have established and continue to explore broad partnership

and collaboration with industry and academic leaders

News Press

News

Abbisko Therapeutics Announces IND Clearance for AB...

06 March 2025, Shanghai—Abbisko Therapeutics Co., Ltd. (“Abbisko” hereafter) today announced that the...

Abbisko Therapeutics Receives CDE Approval to Initi...

December 16, 2024 — Abbisko Therapeutics (HKEX Code: 02256) announced that its self-developed, highly...

2024 ASH Oral Presentation——Abbisko presents promis...

December 8, 2024, Abbisko Therapeutics (HKEX: 02256) announced the presentation of preliminary Phase ...

Press

Bioworld: Abbisko’s pimicotinib meets endpoints in ...

Abbisko Therapeutics Co. Ltd.’s colony-stimulating factor 1 receptor (CSF-1R) inhibitor, pimicotinib,...

PharmaBoardroom interviews Dr. Xu Yaochang, the fou...

Yao-Chang Xu – Founder & CEO, Abbisko “Partnering with a multinational like Merck not only accele...

Bioworld: Abbisko out-licenses pimicotinib to Merck...

Abbisko Therapeutics Co. Ltd. has out-licensed China rights to its colony-stimulating factor 1 recept...

VISION & MISSION

We aspire to become a leading biopharmaceutical company to discover and develop novel and differentiated therapies in cancer and beyond, addressing critical unmet needs for patients in China and globally.

Investors

Since our establishment, we have completed four rounds of financing led by blue-chip investors. Our investor base is a testament to our capabilities and provides strong financial supports and industry insights to our future success.